We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Mobile Blood Gas Analyzer for Hospital POC Launched

By LabMedica International staff writers
Posted on 19 Jul 2012
AACC 2012: A mobile blood gas analyzer, together with a diverse portfolio of new diagnostics testing solutions is launched. More...


Roche Diagnostics (Basel, Switzerland) is showcasing its new technology at the annual American Association of Clinical Chemistry (AACC) meeting Expo in Los Angeles (CA, USA), which is taking place July 15-19, 2012.

The cobas b 123 POC system is a mobile blood gas analyzer that offers next-generation technology that helps ensure reliable performance by virtually eliminating the introduction of blood clots that can contribute to analyzer downtime and negatively impact patient care. The cobas b 123 POC system is designed for hospital point-of-care settings.

The analyzer features a four-level clot protection system that helps prevent clots that can lead to reagent pack failures—a major issue for healthcare facilities because replacing the pack takes time away from patient care and wastes usable reagent. The cobas b 123 POC system also offers automatic linearity testing and calibration to simplify both workflow and regulatory compliance.

The cobas p 312 preanalytical system offers sample management on a small footprint. This front-end automation solution offers comprehensive, vendor-neutral sample management for labs with limited floor space. The compact, standalone system performs sample registration, sorting, decapping, and archiving of all sample tubes—including chemistry, immunoassay, hematology, coagulation, and urinalysis—for the entire laboratory, including non-Roche equipment.

It has a throughput of up to 450 tubes per hour, the system is ideal for customers who are looking for an entry-level step into automation for preanalytical workflow.

The cobas CT/NG Test screens for Chlamydia and gonorrhea infection. A polymerase chain reaction (PCR)-based multiplex dual probe assay, this molecular test is used to screen and diagnose Chlamydia and gonorrhea infection in symptomatic and asymptomatic patients. It runs on the automated cobas 4800 system and offers excellent sensitivity and high specificity. The test uses male urine and self-collected vaginal swabs, which are the preferred specimen types according to the CDC. They show high sensitivity yet are less invasive and less painful to collect than urethral or endocervical samples and thus may help promote screening compliance.

Roche is a biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and CNS. The company is also a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.